In conclusion, our results suggest the EGFR/MET ratio measured in tumors at baseline may help identify NSCLC patients most likely to benefit with prolonged PFS when treated with EGFR inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.